SLC5A2 and type 2 diabetes mellitus: Two ongoing clinical trials are examining the combination of DPP-4 inhibitors and SGLT2 inhibitors (linagliptin plus empagliflozin NCT03429543 and dapagliflozin plus saxagliptin NCT03199053) in youth with T2DM.